Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that lorcaserin data from the Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial will be presented in poster sessions at the American Diabetes Association's (ADA) 71st Scientific Sessions in San Diego, California. The posters highlighted below will be displayed in the Poster Hall from June 25, 2011, at 10:00 a.m. Pacific Time (PT) until June 27, 2011, at 2:00 p.m. PT.
- Randomized, Placebo-Controlled Trial of Lorcaserin for Weight Loss in Patients with Type 2 Diabetes
Author Patrick M. O'Neil, Ph.D., Director, Weight Management Center and Professor at Medical University of South Carolina, will present this poster on June 26 from 12:00 to 2:00 p.m. PT and as part of an ADA guided tour titled Pharmacologic Treatment of Obesity on June 27 from 1:00 to 2:00 p.m. PT. This poster has been assigned presentation number 1878-P in category 19-B Obesity-Human.
- Lorcaserin-Induced Weight Loss and Glycemic Control in Patients with Type 2 Diabetes Mellitus: Data from the BLOOM-DM Study
Author Christen M. Anderson, M.D., Ph.D., Arena's Vice President, Lorcaserin Development, will present this poster during the Presidents Poster Reception on June 26 from 6:45 to 8:00 p.m. PT and the Presidents Poster Session on June 27 from 12:00 to 2:00 p.m. PT. This poster has been assigned presentation number 466-PP.
- Lorcaserin, a Selective 5-HT2C Agonist, Evaluated as a Weight Loss Agent in Obese and Overweight Patients with Type 2 Diabetes Treated with Sulfonylureas or Metformin
Author Ronald L. Shazer, M.D., Arena's Director, Clinical Development, will present this poster on June 26 from 12:00 to 2:00 p.m. PT. This poster has been assigned presentation number 1908-P in category 19-B Obesity-Human.
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options